Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI) -- Ignore unavailable to you. Want to Upgrade?

To: SCOOBEY-DO who wrote (133)	9/29/1999 10:16:00 AM
From: SCOOBEY-DO	Read Replies (1) \| Respond to of 294

Steroidogenesis -STGI- Announces Georgetown University Study To Prevent Retinitis Pigmentosa -RP- In Mice Is Progressing LAS VEGAS--(BW HealthWire)--Sept. 29, 1999--Dr. Alfred T. Sapse, President and CEO of Steroidogenesis Inhibitors International (OTCBB:STGI), received the information from V. Papadopoulos, Ph.D., Pharm.D. Professor - Dept. of Cell Biology at Georgetown University that the Retinitis Pigmentosa Project initiated in March of this year is now moving forward. In most experimental studies using animals, some problems arise in the initial phases. As a positive step forward, those problems have been resolved. The study, officially called "Effect of ANTICORT(TM) on Transgenic Mice Expressing a Mutated Opsin Gene, Stimulating Retinitis Pigmentosa(RP)," is an attempt to prevent Retinitis Pigmentosa genetically induced in mice by techniques developed by Wolfgang Baehr, Ph.D., Professor of Ophthalmology and Neuroscience, Michael Wynn Center for Inherited Retinal Degeneration, Moran Eye Center, University of Utah. The transgenic mice developed by Dr. Baehr were shipped to Georgetown University, and are now being treated with ANTICORT(TM) in an attempt to prevent their litters from developing the genetically inherited RP. The study should progress rapidly from this point forward, given no unforeseen circumstances. Retinitis Pigmentosa (RP) is a term encompassing a group of hereditary retinal degenerations, evolving from night blindness in adolescence to progressive loss of peripheral or central vision after the age of 50, i.e. central or peripheral blindness. In the U.S. there are about 300,000 people suffering various forms of RP. There is no known treatment of this disease. STGI is a pharmaceutical company engaged in the field of developing anti-cortisol drugs intended for the treatment of diseases associated with elevated levels of cortisol, aging, cancers, and Alzheimer's included. This release may include forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For more information visit our World Wide Web page at anticort.com. CONTACT: Steroidogenesis, Las Vegas Janet Greeson, Ph.D., 702/221-0409 or Georgetown University-Office of External Affairs Nancy Whelan, 202/687-4704 or Performance Strategies Richard L. Brown or Chuck Jordan, 303/948-3601